Drug Profile
Research programme: aptamer-based therapeutics - Archemix/Ribomic
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Developer Ribomic
- Class Oligonucleotides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Japan
- 09 Aug 2008 Preclinical trials in Undefined indication in Japan (unspecified route)